The high risk of mold contamination in biopharmaceutical facilities: gypsum wall materials versus uPVC wall panels â regulatory scrutiny, recalls and facility shutdowns

Mold contamination in biopharmaceutical manufacturing is a serious patient-safety, product-quality and regulatory risk. This paper reviews the mechanisms by which wall construction materials contribute to microbial ingress and colonization, compares traditional gypsum (drywall) construction with non-porous wall panel systems such as uPVC/modular panels, and documents regulatory actions, recalls and plant shutdowns linked to fungal contamination. Drawing on industry guidance, inspection findings, and published case histories, it explains why gypsum-based âstick-builtâ walls pose higher long-term mold risk in many life-science environments, and presents engineering, procedural and design strategies to reduce risk (material selection, environmental control, inspection/monitoring, construction sequencing, and remediation policy). Practical recommendations are offered for facility owners, designers, and quality/regulatory teams who must justify capital choices and satisfy regulators.